Results 101 to 110 of about 154,650 (346)

New and emerging treatments for metabolic dysfunction-associated steatohepatitis.

open access: yesCell Metabolism
Metabolic dysfunction-associated steatohepatitis (MASH) is a leading etiology of chronic liver disease worldwide, with increasing incidence and prevalence in the setting of the obesity epidemic. MASH is also a leading indication for liver transplantation,
Monica A. Tincopa, Q. Anstee, R. Loomba
semanticscholar   +1 more source

Spatiotemporal Multi‐Omic Mapping Reveals Liver‐Muscle Metabolic Crosstalk in Cancer Cachexia

open access: yesAdvanced Science, EarlyView.
The interactive CCAtlas platform delineates cross‐species, spatiotemporal, and sex‐specific molecular dynamics and metabolic rewiring across organs during cancer cachexia. Hepatic Gamt downregulation curtails hepatic creatine synthesis to trigger systemic creatine insufficiency and consequent skeletal muscle atrophy in LLC tumour‐bearing mice ...
Zihan Tian   +12 more
wiley   +1 more source

Sinusoidal cell–derived biomarker scores predict diagnosis and prognosis in chronic liver disease

open access: yesBMC Medicine
Background Sinusoidal cells are central drivers of chronic liver disease (CLD) progression, yet current biomarkers fail to capture their phenotypic states.
Sergi Guixé-Muntet   +6 more
doaj   +1 more source

Insulin-like Growth Factor Binding Proteins and Cellular Senescence Are Involved in the Progression of Non-Alcoholic Fatty Liver Disease and Fibrosis in a Mouse Model

open access: yesMedicina
Background and Objectives: Non-alcoholic fatty liver disease (NAFLD) is highly prevalent worldwide. It progresses from simple steatosis to non-alcoholic steatohepatitis (NASH).
Carolina Guzmán   +5 more
doaj   +1 more source

Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis[S]

open access: yesJournal of Lipid Research, 2016
The accumulation of lipids is a histologic and biochemical hallmark of obesity-associated nonalcoholic fatty liver disease (NAFLD). A subset of NALFD patients develops progressive liver disease, termed nonalcoholic steatohepatitis, which is characterized
Petra Hirsova   +3 more
doaj   +1 more source

Role of Cholesterol‐Associated Steatohepatitis in the Development of NASH

open access: yesHepatology Communications, 2021
The rising prevalence of nonalcoholic fatty liver disease (NAFLD) and NAFLD‐related cirrhosis in the United States and globally highlights the need to better understand the mechanisms causing progression of hepatic steatosis to fibrosing steatohepatitis ...
C. Horn   +4 more
semanticscholar   +1 more source

ROS/pH‐Responsive Phenylboronic Acid–Chitosan Nanoparticles Improve Silymarin‐Mediated Hepatoprotection After Hepatectomy With Gut‐Liver Axis‐Associated Responses

open access: yesAdvanced Science, EarlyView.
Bioactive phenylboronic acid–chitosan nanoparticles enable responsive silymarin delivery for post‐hepatectomy liver protection. The nanoplatform integrates antioxidant and antibacterial functions, improves hepatic recovery, and is associated with coordinated shifts in gut microbiota, metabolites, cytokines, and hepatic proteomic pathways, suggesting a ...
Jinjin Tong   +9 more
wiley   +1 more source

Differential hepatotoxicity of dietary and DNL-derived palmitate in the methionine-choline-deficient model of steatohepatitis [PDF]

open access: yes, 2015
© 2015 Pierce et al. Background: Saturated fatty acids are toxic to liver cells and are believed to play a central role in the pathogenesis of non-alcoholic steatohepatitis.
Andrew A. Pierce   +10 more
core   +2 more sources

A Hepatocyte‐to‐Stellate Cell Axis Couples Alternate‐Day Fasting to Liver Fibrosis Resolution via ATG7 S‐Nitrosylation

open access: yesAdvanced Science, EarlyView.
Alternate‐day fasting suppresses mitochondrial complex II assembly via SDHAF4 to upregulate hepatocyte eNOS. The resulting nitric oxide S‐nitrosylates ATG7 at C184 in hepatic stellate cells, restraining autophagic flux and preventing their profibrotic activation.
Xueqiang Wang   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy